See more : HeidelbergCement AG (HDELY) Income Statement Analysis – Financial Results
Complete financial analysis of Targovax ASA (TRVX.OL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Targovax ASA, a leading company in the Biotechnology industry within the Healthcare sector.
- Harfang Exploration Inc. (HAR.V) Income Statement Analysis – Financial Results
- Lookers plc (LKKRF) Income Statement Analysis – Financial Results
- Barksdale Resources Corp. (2NZ.F) Income Statement Analysis – Financial Results
- AGV Products Corporation (1217.TW) Income Statement Analysis – Financial Results
- ShenZhen Woer Heat-Shrinkable Material Co.,Ltd. (002130.SZ) Income Statement Analysis – Financial Results
Targovax ASA (TRVX.OL)
About Targovax ASA
Targovax ASA, a clinical stage immuno-oncology company, engages in the development of immune activators to target hard-to-treat solid tumors. Its lead product candidate is ONCOS-102, which is in Phase I/II clinical trials for the treatment of mesothelioma, melanoma, and colorectal cancer. The company is also developing neoantigen vaccines targeting mutant KRAS cancers. In addition, it is developing ONCOS-211 for next generation ONCOS viruses. The company has collaboration agreements with Cancer Research Institute and Ludwig Cancer Research to develop ONCOS-102 for colorectal cancer with peritoneal carcinomatosis; Valo Therapeutics to develop mutant RAS neoantigen coating of ONCOS viruses using PeptiCRAd technology; and Papyrus Therapeutics to develop novel ONCOS viruses with Receptor Tyrosine Kinase inhibitor functionality. Targovax ASA was incorporated in 2010 and is based in Lysaker, Norway.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10.00M | 0.00 | 624.00K | 2.25M | 27.00K | 37.00K | 37.00K | 146.00K | 72.49K | 364.48K |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 10.00M | 0.00 | 624.00K | 2.25M | 27.00K | 37.00K | 37.00K | 146.00K | 72.49K | 364.48K |
| Gross Profit Ratio | 100.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 47.23M | 37.44M | 45.04M | 80.29M | 68.08M | 49.96M | 51.07M | 9.14M | 0.00 | 0.00 |
| General & Administrative | 5.02M | 4.14M | 7.75M | 10.54M | 11.39M | 12.65M | 12.43M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.02M | 4.14M | 7.75M | 10.54M | 11.39M | 12.65M | 12.43M | 0.00 | 0.00 | 0.00 |
| Other Expenses | 451.35M | 54.02M | 51.74M | 61.70M | 66.65M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 503.59M | 95.60M | 104.52M | 152.53M | 146.13M | 119.96M | 119.55M | 98.13M | 17.64M | 7.83M |
| Cost & Expenses | 503.59M | 95.60M | 104.52M | 152.53M | 146.13M | 119.96M | 119.55M | 98.13M | 17.64M | 7.83M |
| Interest Income | 536.00K | 270.00K | 596.00K | 3.70M | 1.55M | 1.37M | 534.00K | 2.37M | 287.54K | 33.58K |
| Interest Expense | 4.99M | 2.04M | 4.35M | 1.02M | 4.32M | 3.99M | 3.47M | 3.84M | 76.04K | 135.08K |
| Depreciation & Amortization | 395.93M | 923.00K | 3.59M | 7.47M | 308.00K | 296.00K | 284.00K | 148.00K | 10.69K | -8.53K |
| EBITDA | -97.66M | -94.68M | -100.31M | -142.81M | -142.72M | -117.99M | -118.96M | -95.37M | -17.56M | -7.47M |
| EBITDA Ratio | -976.41% | 0.00% | -16,075.96% | -6,344.20% | -528,607.41% | -318,881.08% | -321,513.51% | -65,319.11% | -24,223.45% | -2,049.29% |
| Operating Income | -493.59M | -95.60M | -103.90M | -150.27M | -146.10M | -119.93M | -119.51M | -97.99M | -17.57M | -7.46M |
| Operating Income Ratio | -4,934.92% | 0.00% | -16,650.80% | -6,675.83% | -541,111.11% | -324,124.32% | -323,002.70% | -67,115.14% | -24,237.45% | -2,046.95% |
| Total Other Income/Expenses | -1.74M | -2.42M | -4.50M | 2.42M | -1.25M | -2.35M | -3.20M | -1.47M | -76.58K | -143.61K |
| Income Before Tax | -495.33M | -98.02M | -108.40M | -147.85M | -147.35M | -122.27M | -122.71M | -99.46M | -17.65M | -7.60M |
| Income Before Tax Ratio | -4,952.29% | 0.00% | -17,372.28% | -6,568.19% | -545,737.04% | -330,467.57% | -331,659.46% | -68,122.88% | -24,343.08% | -2,086.35% |
| Income Tax Expense | -62.43M | -52.00K | -277.00K | -321.00K | -334.00K | -328.00K | -260.00K | 1.93M | -542.00 | 0.00 |
| Net Income | -432.90M | -97.97M | -108.13M | -147.53M | -147.02M | -121.95M | -122.45M | -101.39M | -17.65M | -7.60M |
| Net Income Ratio | -4,328.11% | 0.00% | -17,327.88% | -6,553.93% | -544,500.00% | -329,581.08% | -330,956.76% | -69,444.79% | -24,343.08% | -2,086.35% |
| EPS | -2.30 | -1.10 | -1.15 | -1.99 | -2.29 | -2.06 | -2.78 | -2.96 | -1.96 | -0.22 |
| EPS Diluted | -2.30 | -1.10 | -1.15 | -1.99 | -2.29 | -2.06 | -2.78 | -2.96 | -1.96 | -0.22 |
| Weighted Avg Shares Out | 188.43M | 89.08M | 94.28M | 74.30M | 64.33M | 59.29M | 43.99M | 34.25M | 8.99M | 34.26M |
| Weighted Avg Shares Out (Dil) | 188.43M | 89.08M | 94.28M | 74.30M | 64.33M | 59.29M | 43.99M | 34.25M | 8.99M | 34.26M |
Source: https://incomestatements.info
Category: Stock Reports